Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Melanoma: HELP
Articles by Clay J. Cockerell
Based on 12 articles published since 2010
(Why 12 articles?)
||||

Between 2010 and 2020, Clay Cockerell wrote the following 12 articles about Melanoma.
 
+ Citations + Abstracts
1 Editorial Counterpoint: The "dysplastic" nevus: What I do and do not believe. 2015

Cockerell, Clay J. ·Department of Dermatology, University of Texas Southwestern Medical Center, and Cockerell Dermatopathology, Dallas, Texas. Electronic address: ccockerell@dermpath.com. ·J Am Acad Dermatol · Pubmed #26282799.

ABSTRACT: -- No abstract --

2 Review Integrating Skin Cancer-Related Technologies into Clinical Practice. 2017

Winkelmann, Richard R / Farberg, Aaron S / Glazer, Alex M / Cockerell, Clay J / Sober, Arthur J / Siegel, Daniel M / Leachman, Sancy A / High, Whitney A / Markowitz, Orit / Berman, Brian / Pariser, David M / Goldenberg, Gary / Rosen, Theodore / Rigel, Darrell S. ·Department of Dermatology, OhioHealth, 75 Hospital Drive STE 250, Athens, OH 4570, USA. · Department of Dermatology, Icahn School of Medicine at Mt. Sinai, 1425 Madison Avenue, Floor 2, New York, NY 10029, USA. · National Society for Cutaneous Medicine, 35 East 35th Street #208, New York, NY 10016, USA. · Department of Dermatology, The University of Texas Southwestern Medical Center, 5939 Harry Hines Boulevard. 4th Floor, Suite 100, Dallas, TX 75390, USA. · Department of Dermatology, Harvard Medical School, 50 Staniford Street, 2nd Floor, Boston, MA 02114, USA. · Department of Dermatology, SUNY Downstate Medical Center, 450 Clarkson Avenue, Brooklyn, NY 11203, USA. · Department of Dermatology, OHSU Knight Cancer Institute, Oregon Health & Science University, 3303 S.W. Bond Avenue, Portland, OR 97239, USA. · Department of Dermatology & Pathology, University of Colorado School of Medicine, 12635 E Montview Boulevard, Bioscience Park, Suite 160, Aurora, CO 80045, USA. · Department of Dermatology, Mount Sinai Medical Center, 5 E 98th Street, FL 5, New York, NY 10029, USA. · Department of Dermatology, University of Miami Miller School of Medicine, 2925 Aventura Boulevard, Suite 205, Aventura, FL 33180, USA. · Department of Dermatology, Eastern Virginia Medical School, 6160 Kempsville Circle, Suite 200A, Norfolk, VA 23502, USA. · Department of Dermatology, Baylor College of Medicine, 1977 Butler Street, Suite E6.200, Houston, Texas 77030, USA. · Department of Dermatology, NYU School of Medicine, 35 East 35th Street #208, New York, NY 10016, USA. Electronic address: dsrigel@prodigy.net. ·Dermatol Clin · Pubmed #28886814.

ABSTRACT: Early diagnosis and treatment of melanoma improve survival. New technologies are emerging that may augment the diagnosis, assessment, and management of melanoma but penetrance into everyday practice is low. In the current health care climate, greater emphasis will be placed on the incorporation of technology for clinically suspicious pigmented lesions to facilitate better, more cost-effective management.

3 Review The pathology of melanoma. 2012

Cockerell, Clay J. ·Department of Dermatology, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA. ccockerell@skincancer.com ·Dermatol Clin · Pubmed #22800551.

ABSTRACT: Although melanoma represents only 10% of all skin cancer diagnoses, it accounts for at least 65% of all skin cancer-related deaths. The number of new cutaneous melanoma cases projected during 2010 was 68,000-a 23% increase from the 2004 prediction of 55,100 cases. In 2015, the lifetime risk of developing melanoma is estimated to increase to 1 in 50. As the incidence of melanoma continues to rise, now more than ever, clinicians and histopathologists must have familiarity with the various clinical and pathologic features of cutaneous melanoma.

4 Article Impact on clinical practice of a non-invasive gene expression melanoma rule-out test: 12-month follow-up of negative test results and utility data from a large US registry study. 2019

Ferris, Laura K / Rigel, Darrell S / Siegel, Daniel M / Skelsey, Maral K / Peck, Gary L / Hren, Catherine / Gorman, Christopher / Frumento, Tana / Jansen, Burkhard / Yao, Zuxu / Rock, Jim / Knezevich, Stevan R / Cockerell, Clay J. ·Department of Dermatology, University of Pittsburgh, Pittsburgh, PA. ferrislk@upmc.edu. ·Dermatol Online J · Pubmed #31220892.

ABSTRACT: The Pigmented Lesion Assay (PLA, sensitivity 91-95%, specificity 69-91%, negative predictive value ?99%) is a commercially available, non-invasive gene expression test that helps dermatologists guide pigmented lesion management decisions and rule out melanoma. Earlier studies have demonstrated high clinical utility and no missed melanomas in a 3-6-month follow-up period. We undertook the current investigations to provide 12-month follow-up data on PLA(-) tests, and to further confirm utility. A 12-month chart review follow-up of 734 pigmented lesions that had negative PLA results from 5 US dermatology centers was performed. Thirteen of these lesions (1.8%) were biopsied in the follow-up period and submitted for histopathologic review. None of the lesions biopsied had a histopathologic diagnosis of melanoma. The test's utility was studied further in a registry (N=1575, 40 US dermatology offices, 62 participating providers), which demonstrated that 99.9% of PLA(-) lesions were clinically monitored, thereby avoiding a surgical procedure, and 96.5% of all PLA(+) lesions were appropriately biopsied, most commonly with a tangential shave. This long-term follow-up study confirms the PLA's high negative predictive value and high utility in helping guide the management of pigmented lesions to avoid unnecessary surgical procedures.

5 Article Noninvasive Analysis of High-Risk Driver Mutations and Gene Expression Profiles in Primary Cutaneous Melanoma. 2019

Ferris, Laura K / Moy, Ronald L / Gerami, Pedram / Sligh, James E / Jansen, Burkhard / Yao, Zuxu / Cockerell, Clay J. ·Department of Dermatology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. Electronic address: ferrlk@upmc.edu. · RodeoDerm Moy Fincher Chips, Beverly Hills, California, USA. · Department of Dermatology, Northwestern University, Chicago, Illinois, USA. · Southern Arizona Veterans Affairs Healthcare System and University of Arizona, Tucson, Arizona, USA. · DermTech, Inc., La Jolla, California, USA. · Cockerell Dermatopathology, Dallas, Texas, USA. ·J Invest Dermatol · Pubmed #30500343.

ABSTRACT: Tools that help reduce the number of surgical biopsies performed on benign lesions have the potential to improve patient care. The pigmented lesion assay (PLA) is a noninvasive tool validated against histopathology that helps rule out melanoma and the need for surgical biopsies of atypical pigmented skin lesions. Genetic information is collected using adhesive patches and the expression of two genes, LINC and PRAME, is measured. By using genetic material collected noninvasively and to further validate the PLA, somatic hotspot mutations in genes known to be drivers of early melanoma development (BRAF other than V600E, NRAS, and the TERT promoter) can also be identified. The frequency of these hotspot mutations in samples of early melanoma was 77%, which is higher than the 14% found in nonmelanoma samples (P < 0.0001). TERT promoter mutations were the most prevalent mutation type in PLA-positive melanomas; 82% of PLA-negative lesions had no mutations, and 97% of histopathologically confirmed melanomas were PLA and/or mutation positive (cohort 1, n = 103). Mutation frequencies were similar in prospectively collected real-world PLA samples (cohort 2, n = 519), in which 88% of PLA-negative samples had no mutations. Combining gene expression and mutation analyses enhances the ability to noninvasively detect early cutaneous melanoma.

6 Article Commentary on Atypical Melanocytic Proliferations. 2018

Cockerell, Clay J. ·Division of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas. ·Dermatol Surg · Pubmed #29401162.

ABSTRACT: -- No abstract --

7 Article The influence of a gene-expression signature on the treatment of diagnostically challenging melanocytic lesions. 2017

Cockerell, Clay / Tschen, Jaime / Billings, Steven D / Evans, Brent / Brown, Krystal / Rock, Colleen / Clarke, Loren E. ·Cockerell Dermatopathology & University of Texas Southwestern Medical Center, 2110 Research Row #100, Dallas, TX 75235, USA. · St Joseph Medical Center, 6909 Greenbriar Drive, Houston, TX 77030, USA. · Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH 44106, USA. · Myriad Genetic Laboratories, Inc., 320 Wakara Way, Salt Lake City, UT 84108, USA. ·Per Med · Pubmed #28757886.

ABSTRACT: AIM: The effect of a gene-expression-based test on treatment of melanocytic neoplasms by dermatologists was evaluated. PATIENTS & METHODS: Pathologists submitted diagnostically challenging melanocytic neoplasms to a clinical laboratory for testing accompanied by pretest surveys documenting the intended treatment recommendations. The actual treatment rendered by dermatologists was then documented after testing. Changes between the pretest recommendations and actual treatment were analyzed. RESULTS: In 71.4% (55/77) of cases, there was a change from pretest recommendations to actual treatment. The majority of changes were consistent with the test result. There was an 80.5% (33/41) reduction in the number of biopsy site re-excisions performed for cases with a benign test result. CONCLUSION: The actual treatment of diagnostically challenging melanocytic neoplasms is influenced by the test.

8 Article An independent validation of a gene expression signature to differentiate malignant melanoma from benign melanocytic nevi. 2017

Clarke, Loren E / Flake, Darl D / Busam, Klaus / Cockerell, Clay / Helm, Klaus / McNiff, Jennifer / Reed, Jon / Tschen, Jaime / Kim, Jinah / Barnhill, Raymond / Elenitsas, Rosalie / Prieto, Victor G / Nelson, Jonathan / Kimbrell, Hillary / Kolquist, Kathryn A / Brown, Krystal L / Warf, M Bryan / Roa, Benjamin B / Wenstrup, Richard J. ·Myriad Genetic Laboratories, Inc, Salt Lake City, Utah. · Myriad Genetics, Inc, Salt Lake City, Utah. · Memorial Sloan Kettering Cancer Center, New York, New York. · The University of Texas Southwestern Medical Center, Dallas, Texas. · Penn State Hershey Dermatology, Hershey, Pennsylvania. · Yale Dermatopathology, New Haven, Connecticut. · CellNetix Pathology and Laboratories LLC, Seattle, Washington. · St. Joseph Dermatopathology, Houston, Texas. · Department of Pathology, Stanford School of Medicine, Stanford, California. · Department of Pathology, University of California Los Angeles, Los Angeles, California. · Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania. · Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas. ·Cancer · Pubmed #27768230.

ABSTRACT: BACKGROUND: Recently, a 23-gene signature was developed to produce a melanoma diagnostic score capable of differentiating malignant and benign melanocytic lesions. The primary objective of this study was to independently assess the ability of the gene signature to differentiate melanoma from benign nevi in clinically relevant lesions. METHODS: A set of 1400 melanocytic lesions was selected from samples prospectively submitted for gene expression testing at a clinical laboratory. Each sample was tested and subjected to an independent histopathologic evaluation by 3 experienced dermatopathologists. A primary diagnosis (benign or malignant) was assigned to each sample, and diagnostic concordance among the 3 dermatopathologists was required for inclusion in analyses. The sensitivity and specificity of the score in differentiating benign and malignant melanocytic lesions were calculated to assess the association between the score and the pathologic diagnosis. RESULTS: The gene expression signature differentiated benign nevi from malignant melanoma with a sensitivity of 91.5% and a specificity of 92.5%. CONCLUSIONS: These results reflect the performance of the gene signature in a diverse array of samples encountered in routine clinical practice. Cancer 2017;123:617-628. © 2016 American Cancer Society.

9 Article The influence of a gene expression signature on the diagnosis and recommended treatment of melanocytic tumors by dermatopathologists. 2016

Cockerell, Clay J / Tschen, Jaime / Evans, Brent / Bess, Emily / Kidd, John / Kolquist, Kathryn A / Rock, Colleen / Clarke, Loren E. ·aDepartment of Dermatology and Pathology, University of Texas Southwestern Medical Center, Dallas bSt. Joseph Dermatopathology, Houston, TX cClinical Affairs dDepartment of Dermatology eDepartment of Histopathology, Myriad Genetic Laboratories, Inc., Salt Lake City, UT. ·Medicine (Baltimore) · Pubmed #27749545.

ABSTRACT: It is well documented that histopathologic examination is sometimes inadequate for accurate and reproducible diagnosis of certain melanocytic neoplasms. Recently, a 23-gene expression signature has been clinically validated as an adjunctive diagnostic test to differentiate benign nevi from malignant melanomas. This study aimed to quantify the impact of this test on diagnosis and treatment recommendations made by dermatopathologists.Diagnostically challenging melanocytic lesions encountered during routine dermatopathology practice were submitted for gene expression testing and received a melanoma diagnostic score (MDS). Submitting dermatopathologists completed a survey documenting pre-test diagnosis, level of diagnostic confidence, and recommendations for treatment. The survey was repeated after receiving the MDS. Changes between the pre- and post-test surveys were analyzed retrospectively.When the MDS was available as part of a comprehensive case evaluation in diagnostically challenging cases, definitive diagnoses were increased by 56.6% for cases that were initially indeterminate and changes in treatment recommendations occurred in 49.1% of cases. Treatment recommendations were changed to align with the test result in 76.6% of diagnostically challenging cases.The MDS impacts diagnosis and treatment recommendations by dermatopathologists confronted with diagnostically challenging melanocytic lesions. Increased data are needed in order to completely understand how use of the MDS will translate from dermatopathology to clinical practice.

10 Article Mitotic rate in cutaneous melanomas ≤1 mm in thickness: a prospective study. 2012

Litzner, Brandon R / Etufugh, Chukwuemeka N / Stepenaskie, Shelly / Hynan, Linda S / Cockerell, Clay J. ·Department of Dermatology, University of Texas-Southwestern Medical Center, Dallas, TX 75390-9069, USA. brandon.litzner@phhs.org ·Am J Dermatopathol · Pubmed #22878366.

ABSTRACT: The mitotic rate (MR) of malignant melanoma (MM) refers to the number of mitoses per square millimeter. Studies have suggested that it is an independent prognostic variable predicting survival in patients with MM, and it was recently included in the American Joint Committee on Cancer (AJCC) recommendations for diagnosis and treatment of MM. The AJCC melanoma staging committee recommends using the "hot-spot" approach to determine the MR, whereby it is reported as the maximum dermal mitotic figures identified in a 1-mm area of the melanoma. The AJCC has recommended that the MR be determined in all melanomas, irrespective of Breslow depth or other features. We aimed to quantify the MR in MM ≤1 mm in thickness and to identify statistical associations between the MR, Breslow depth, and Clark level. In addition, we hoped to identify practical issues in determining the MR via the hot-spot technique. We conducted a prospective study to determine the MR, Breslow depth, and Clark level in MM ≤1 mm in thickness. Seven melanomas were identified with epidermal mitoses only (7.4%). Sixteen melanomas had dermal mitoses (16.8%); of these, the majority (75.0%) contained only one mitotic figure. Seventy-nine melanomas had no dermal mitoses (83.2%). Seven lesions (7.4%) demonstrated multiple mitoses; 4 with ≥2 dermal mitoses/mm and 3 with multiple epidermal mitoses. We conclude that thin MM with >1 mitosis/mm is rare and discuss practical and theoretical issues with determining the MR using the hot-spot approach.

11 Minor Hidradenitis suppurativa, eruptive melanocytic nevi, and keratosis pilaris-like eruption in a patient treated with vemurafenib. 2012

Ma, Liqiao / Dominguez, Arturo R / Collins, George R / Kia, Kevin F / Cockerell, Clay J. · ·Arch Dermatol · Pubmed #23247496.

ABSTRACT: -- No abstract --

12 Minor Impact of guidance from a computer-aided multispectral digital skin lesion analysis device on decision to biopsy lesions clinically suggestive of melanoma. 2012

Rigel, Darrell S / Roy, Mrinalini / Yoo, Jane / Cockerell, Clay J / Robinson, June K / White, Richard. · ·Arch Dermatol · Pubmed #22351788.

ABSTRACT: -- No abstract --